{
    "clinical_study": {
        "@rank": "30274", 
        "acronym": "uPARCRPC", 
        "arm_group": {
            "arm_group_label": "Castration-resistant prostate cancer, Progression after taxane", 
            "description": "Treated with abiraterone 1000 mg/day Prednisolone 10 mg/day"
        }, 
        "biospec_descr": {
            "textblock": "Blood plasma"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate cleavage products of the urokinase\n      plasminogenactivator receptor (uPAR) in plasma from patients with castration resistant\n      prostate cancer as a predictive marker of response to abiraterone."
        }, 
        "brief_title": "Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer", 
        "condition": "Prostatic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent.\n\n          -  Age \u226518 years and male\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the prostate without\n             neuroendocrine differentiation or small cell histology\n\n          -  Received at least one but not more than two cytotoxic chemotherapy regimens for\n             metastatic CRPC. At least one regimen must have contained a taxane such as docetaxel.\n\n          -  Prostate cancer progression as assessed by the investigator with one of the\n             following:\n\n               -  PSA progression according to Prostate Cancer Working Group 2 (PCWG2) criteria\n\n               -  Solid Tumors (RECIST) criteria or bone scans with or without PSA progression.\n\n               -  Radiographic progression in soft tissue according to Response Evaluation\n                  Criteria in\n\n          -  Ongoing androgen deprivation with serum testosterone <2.0 nM\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of \u22642\n\n          -  Platelet count \u2265100,000/\u03bcL\n\n          -  Serum albumin \u226530 g/dL\n\n          -  Serum creatinine <1.5 x upper limit of normal (ULN) or a calculated creatinine\n             clearance \u2265 60 mL/min\n\n          -  Serum potassium \u22653.5 mmol/L\n\n        Exclusion Criteria:\n\n          -  Received abiraterone or MDV3100 in the past.\n\n          -  Serious or uncontrolled co-existent non-malignant disease, including active and\n             uncontrolled infection.\n\n          -  Abnormal liver functions consisting of any of the following:\n\n               -  Serum bilirubin \u22651.5 x ULN (except for subjects with documented Gilbert's\n                  disease, for whom the upper limit of serum bilirubin is 51 \u00b5mol/l)\n\n               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \u22652.5 x ULN\n\n          -  Uncontrolled hypertension (systolic blood pressure \u2265160 mmHg or diastolic blood\n             pressure \u226595 mmHg); subjects with a history of hypertension are allowed provided\n             blood pressure is controlled by anti-hypertensive therapy.\n\n          -  Active or symptomatic viral hepatitis or chronic liver disease\n\n          -  History of pituitary or adrenal dysfunction\n\n          -  Clinically significant heart disease as evidenced by myocardial infarction, or\n             arterial thrombotic events in the past 6 months, severe or unstable angina, or New\n             York Heart Association (NYHA) Class III or IV heart disease or left ventricular\n             ejection fraction (LVEF) of <50% at baseline.\n\n          -  Known brain metastasis\n\n          -  History of gastrointestinal disorders (medical disorders or extensive surgery) that\n             may interfere with the absorption of the study drug\n\n          -  Any acute toxicities due to prior chemotherapy or radiotherapy that have not resolved\n             to a NCI-CTCAE (Version 4.0) Grade of \u22641. Chemotherapy induced alopecia and Grade 2\n             peripheral neuropathy is allowed.\n\n          -  Use of other anticancer therapy including cytotoxic, radionucleotide, and\n             immunotherapy; diethylstilbestrol; PC-SPES; spironolactone (ie, ALDACTONE, SPIRONOL);\n             and other preparations such as saw palmetto thought to have endocrine effects on\n             prostate cancer, within 4 weeks of Cycle 1 Day 1\n\n          -  Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole,\n             ketoconazole) within 4 weeks of Cycle 1 Day 1\n\n          -  Current enrolment in an investigational drug or device study or participation in such\n             a study within 30 days of Day 1\n\n          -  Condition or situation which, in the investigator's opinion, may put the subjects at\n             significant risk, may confound the study results, or may interfere significantly with\n             subject's participation in the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients eligible for this study include patients with CRPC in progression after therapy\n        with a taxane who are candidates for therapy with standard second line therapy\n        abiraterone."
            }
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125617", 
            "org_study_id": "uPARCRPC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Castration-resistant prostate cancer, Progression after taxane", 
                "description": "1000 mg/day", 
                "intervention_name": "Abiraterone", 
                "intervention_type": "Drug", 
                "other_name": "Zytiga\u00ae"
            }, 
            {
                "arm_group_label": "Castration-resistant prostate cancer, Progression after taxane", 
                "description": "10 mg/day", 
                "intervention_name": "Prednisolone", 
                "intervention_type": "Drug", 
                "other_name": "Prednisolone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Prednisolone", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate", 
                "Plasminogen"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Castration-resistant prostate cancer", 
            "Abiraterone", 
            "Biomarker", 
            "Urokinase Plasminogen Activator Receptor", 
            "Plasma", 
            "Predictive markers"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "contact": {
                "email": "kristoffer@onkolog.dk", 
                "last_name": "Kristoffer Rohrberg, MD, Phd", 
                "phone": "+45 35459697"
            }, 
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "zip": "2100"
                }, 
                "name": "University Hospital of Copenhagen, Rigshospitalet"
            }, 
            "investigator": [
                {
                    "last_name": "Kristoffer S Rohrberg, MD, Phd", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Helle Pappot, MD, DMSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Gedske Daugaard, MD, DMSc", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_groups": "1", 
        "official_title": "uPAR in Blood From Zytiga\u00ae (Abiraterone) Treated Patients With Castration Resistant Prostate Cancer - a Predictive Marker of Response?", 
        "overall_contact": {
            "email": "kristoffer@onkolog.dk", 
            "last_name": "Kristoffer S Rohrberg, MD, Phd", 
            "phone": "+45 35459697"
        }, 
        "overall_contact_backup": {
            "email": "helle.pappot@regionh.dk", 
            "last_name": "Helle Pappot, MD, DMSc", 
            "phone": "+45 35458403"
        }, 
        "overall_official": {
            "affiliation": "Rigshospitalet, Denmark", 
            "last_name": "Kristoffer S Rohrberg, MD, Phd", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: Ethics Committee", 
                "Denmark: The Regional Committee on Biomedical Research Ethics"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Impact of baseline plasma concentration of uPAR cleavage products on overall response rate (ORR) defined as the proportion of patients with radiologic response according to the RECIST criteria or PSA-response.", 
            "measure": "Impact of baseline uPAR cleavage products on response.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125617"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rigshospitalet, Denmark", 
            "investigator_full_name": "Kristoffer Staal Rohrberg", 
            "investigator_title": "MD, Phd", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Impact of baseline plasma concentration of uPAR cleavage products on overall survival (OS).", 
                "measure": "Impact of baseline plasma concentration of uPAR cleavage products on overall survival (OS).", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Impact of baseline plasma concentration of uPAR cleavage products on progression free survival (PFS).", 
                "measure": "Impact of baseline plasma concentration of uPAR cleavage products on progression free survival (PFS).", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Impact of baseline plasma concentration of uPAR cleavage products on pain relief rate.", 
                "measure": "Impact of baseline plasma concentration of uPAR cleavage products on pain relief rate.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Impact of baseline plasma concentration of uPAR cleavage products on disease control rate (DCR).", 
                "measure": "Impact of baseline plasma concentration of uPAR cleavage products on disease control rate (DCR).", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Impact of baseline plasma concentration of uPAR cleavage products on serious adverse events (SAE).", 
                "measure": "Impact of baseline plasma concentration of uPAR cleavage products on serious adverse events (SAE).", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Rigshospitalet, Denmark", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen-Cilag Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Kristoffer Staal Rohrberg", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}